Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
cbdMD Review
A 60-day money-back guarantee is only as good as the company behind it. This one has told the SEC there is substantial doubt it survives the next twelve months.
cbdMD
Going-Concern QualificationRead this before anything else: cbdMD's own 10-K for the year ended 30 September 2025 states that factors “raise substantial doubt about the Company’s ability to continue as a going concern within twelve months”. That is the filed language, not our characterisation. It is the essential context for the 60-day refund, any subscription, and any gift card.
The company is real and reporting: NYSE American as YCBD, audited accounts, a $2.04m net loss for the year to 30 September 2025 narrowing from prior years, cash of $2.64m and stockholders' equity of $9.28m at 31 March 2026, and back in compliance with exchange listing standards after a one-for-eight reverse split in May 2025. The 60-day full-refund policy is genuinely generous for the category.
Two more things. The catalogue now leans into THC drinks — and a 170mg THC Mixer is roughly 425 times the 0.4mg per-container cap arriving 12 November 2026. And in fairness to cbdMD, its filing states candidly that the FDA “continues to assert that CBD cannot be lawfully marketed as a dietary supplement or added to human food” — which most CBD marketing never mentions.
Affiliate disclosure: GLP1Drugs.org uses affiliate links. Worth stating plainly here: this programme pays 0.00% commission, so we earn nothing whether you buy or not. Financial figures come from cbdMD's own SEC filings. Verified 8 August 2026.
Visit cbdMDOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
12mo
Going-Concern Doubt Window
60
Day Refund It Underwrites
425×
170mg Mixer Over The Nov Cap
0%
Commission This Offer Pays Us
What The Filings Disclose
Six findings taken from cbdMD's own SEC filings and product pages, not from press coverage.
Its Own Filing Flags Substantial Doubt
The 10-K for the year ended 30 September 2025 states that factors 'raise substantial doubt about the Company's ability to continue as a going concern within twelve months' after the accounts were issued
Which Is The Context For The 60-Day Refund
cbdMD offers a full refund within 60 days. A refund promise is worth exactly what the company behind it is worth, so the two facts have to be read together rather than separately
A One-For-Eight Reverse Split In May 2025
The board effected a reverse stock split at a ratio of one-for-eight effective 6 May 2025 — normally done to lift a share price back above an exchange's minimum
It Had Fallen Out Of Listing Compliance
The 10-K describes regaining compliance with NYSE American continued listing standards, including a minimum stockholders' equity requirement of $6,000,000, and says non-compliance has been removed
The Filing Is Candid About CBD's Legal Status
To its credit, the 10-K states plainly that the FDA 'continues to assert that CBD cannot be lawfully marketed as a dietary supplement or added to human food' — something the marketing does not mention
And A 170mg THC Mixer Faces A 0.4mg Cap
From 12 November 2026, consumables are limited to 0.4mg total THC per innermost container. The 170mg THC Mixer is roughly 425 times that figure
Where Your Money Sits, And For How Long
With a going-concern qualification on file, the safest purchases are the ones that leave nothing with the company.
| How you buy | What the company holds | Our view |
|---|---|---|
| One item, credit card | Nothing once it ships; you keep a chargeback route | Reasonable |
| Large stock-up | Nothing, but your refund route is the 60-day promise | Avoid — do not rely on returning it |
| Subscription | A recurring claim on your card for future shipments | No |
| Gift card | Your cash, as an unsecured liability on its balance sheet | No |
| Reward points | A promise of future value, not property | Redeem promptly, do not accumulate |
To be clear, this is not a prediction that cbdMD will fail — it is trading, back in listing compliance, and its losses are narrowing. It is the ordinary consequence of the disclosure the company itself made. If you are here about treatment rather than supplements, our provider rankings and side-effects guide are the right pages.
Pros & Cons
Pros
- ✓A 60-day money-back guarantee: 'If you are not fully satisfied with your purchase, you may request a full refund on the purchase price within 60 days'
- ✓A real SEC-reporting company with audited accounts, a board, and disclosure obligations — you can check the facts rather than take marketing on trust
- ✓Unusually candid in its own filing about the regulatory position, acknowledging the FDA asserts CBD cannot lawfully be sold as a dietary supplement or added to food
- ✓The same filing acknowledges FDA enforcement against the category for 'unapproved drug claims, mislabeling, inadequate testing, and non-compliant animal products'
- ✓The 10-K describes real quality infrastructure: environmental controls, FEFO inventory rotation, product-level traceability and documented recall protocols
- ✓Losses have narrowed — a $2.04m net loss for the year to 30 September 2025, and $1.08m across the six months to 31 March 2026
- ✓Stockholders' equity rose across recent quarters to $9.28m at 31 March 2026, and the company is back in compliance with NYSE American listing standards
- ✓Broad range across tinctures, gummies, softgels, topicals, beverages and pet products, with a dedicated COA page in the site footer
- ✓Dose options are granular on the THC line — 5mg, 10mg and 18mg per serving — which supports starting low
Cons
- ✕The 10-K carries an explicit going-concern qualification: substantial doubt about continuing as a going concern within twelve months
- ✕The company states its survival 'is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding'
- ✕Cash stood at $2.64m at 31 March 2026 against continuing losses — a thin buffer for a business of this kind
- ✕A one-for-eight reverse stock split in May 2025, and a prior period of non-compliance with NYSE American continued listing standards
- ✕The 60-day guarantee, the reward scheme and any subscription all depend on the company being there to honour them
- ✕Trustpilot holds only 26 reviews at 2.6 out of 5 — both thin and mediocre
- ✕No BBB profile came up in our search
- ✕The affiliate programme pays 0.00% commission on this offer, so nobody writing about it is being paid to recommend it — including us
- ✕Prices are high for the category: $159.99 for a CBD + CBN tincture, $104.99 for a topical roller, $84.99 for full-spectrum gummies
- ✕'55% Off Sitewide' promotion running when we checked, which is deep discounting rather than confident pricing
- ✕The THC beverage line — a 170mg mixer, 30mg seltzers and shots — cannot survive the 0.4mg per-container federal cap in November 2026
- ✕We could not retrieve any individual certificate from the COA page, so we could not verify batch testing ourselves
Our Verdict
2.6 / 5 — a legitimate, unusually candid company offering a 60-day guarantee it has told regulators it may not be around to honour.
There is a lot to respect here, and it is worth setting out before the criticism. cbdMD is an SEC-reporting company with audited accounts, a board and real disclosure obligations, which means you can check facts about it rather than trusting a landing page. Its 60-day full-refund policy is more generous than most of the category. Its 10-K describes genuine quality infrastructure — environmental controls, FEFO inventory rotation, product-level traceability, documented recall protocols. And most unusually, that filing states plainly that the FDA 'continues to assert that CBD cannot be lawfully marketed as a dietary supplement or added to human food', and acknowledges the warning letters the agency has sent the category for unapproved drug claims, mislabelling and inadequate testing. Almost no CBD brand says that anywhere.
The problem is what the same filing says about the company itself. For the year ended 30 September 2025 it discloses that factors 'raise substantial doubt about the Company's ability to continue as a going concern within twelve months', that it has a history of losses with no assurance of profitable operations, and that continuing depends on improving cash flow and 'the ability to acquire additional funding'. Behind that sit a $2.04m annual loss, $2.64m of cash at 31 March 2026, a one-for-eight reverse stock split in May 2025 and a period out of compliance with NYSE American's listing standards. In fairness: losses are narrowing, equity has risen to $9.28m, and the company is back in compliance. This is a business under strain that is improving, and we are not predicting its failure.
But it changes the advice, and the advice is specific rather than dramatic. Buy one item, on a credit card, and take delivery. Do not stock up on the strength of the 60-day guarantee, do not subscribe, do not buy gift cards, and do not bank reward points for later — each of those leaves your money with a company that has disclosed doubt about its own continuity. Two other things weigh on the score: Trustpilot holds just 26 reviews at 2.6 with no BBB profile, so there is almost no independent record; and we could not open a single certificate from the COA page, which is a failure to verify rather than evidence of no testing, but it is a gap. Finally, the THC beverage line has a hard stop — a 170mg mixer against a 0.4mg per-container cap on 12 November 2026 is not a rounding problem. In the interest of full disclosure: this programme pays us nothing, 0.00% commission, so there is no version of this page where we benefit from your clicking.
Visit cbdMDFrequently Asked Questions
What is a going-concern qualification and why does it matter here?
It is the most serious thing a company can disclose about itself, and cbdMD discloses it. In its annual report on Form 10-K for the fiscal year ended 30 September 2025, the company states that certain factors 'raise substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the annual financial statements are issued', that it has 'a history of losses from operations and there are no assurances we will report profitable operations in future periods or continue as a going concern', and that its ability to continue 'is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding'. That is not our characterisation; it is the filed language. In plain terms, a going-concern qualification means the company and its auditors judge that there is meaningful uncertainty about whether it can keep operating for another year without new money. It is not a prediction of failure — many companies carry the qualification and trade out of it, and cbdMD's own numbers have been improving. But it changes how you should treat any promise that extends into the future, and this company's main consumer promise is a 60-day refund.
Is the 60-day money-back guarantee safe to rely on?
The terms are good and the counterparty is the question. The stated policy is straightforward and generous by category standards: 'If you are not fully satisfied with your purchase, you may request a full refund on the purchase price within 60 days.' Sixty days is longer than most CBD brands offer, and a full refund on the purchase price is a clear commitment. The difficulty is that a guarantee is a promise about the future, and the company has told the SEC there is substantial doubt about its ability to keep operating for twelve months. So the guarantee is only as strong as the business behind it, and that business currently reports $2.64m of cash against continuing losses. This does not make the guarantee worthless — the company is trading, is back in compliance with its exchange's listing standards, and has positive equity of $9.28m. It means you should not plan around it. Practical approach: buy one item rather than a large stock-up, pay by credit card so you have a chargeback route independent of the company's own refund process, request any refund early in the window rather than on day 59, and keep your order confirmation. Do not buy a large quantity on the theory that you can always send it back.
Should I start a subscription or buy gift cards?
No, and for the same reason. A subscription is a commitment to send a company money in the future in exchange for goods it will ship later; a gift card is money handed over now for merchandise later. Both convert cash into a claim on a business, and cbdMD has filed a going-concern qualification. If a company restructures, gift card holders and prepaid customers are unsecured creditors, and outstanding balances are frequently honoured only partly, only briefly, or not at all. Loyalty and reward points sit in the same category — they are a promise, not property. None of this is a prediction about cbdMD. It is the ordinary consequence of the disclosure the company itself made, and it points to one simple behaviour: pay for what you want when you want it, take delivery, and do not leave value sitting with the business. If there is a subscription discount you find genuinely compelling, weigh it against the fact that the saving is small and the exposure is your money. One-off purchases on a credit card is the sensible way to buy from any company in this position.
Does cbdMD admit CBD is not an approved supplement?
Yes, and this is the most creditable thing we found. Buried in its 10-K rather than on any product page, cbdMD states that the FDA 'continues to assert that CBD cannot be lawfully marketed as a dietary supplement or added to human food under existing statutory authorities due to CBD's prior investigation as an approved drug'. It goes further and acknowledges that FDA enforcement in the category 'has included warning letters for unapproved drug claims, mislabeling, inadequate testing, and non-compliant animal products', and that this position 'has been outlined in the majority of Warning Letters the FDA has sent to CBD companies since the enactment of the Farm Bill'. That is an accurate description of the regulatory position and most CBD companies never say it anywhere. The reason it appears in the 10-K and not the marketing is that securities law requires companies to disclose material risks to investors, whereas nothing requires the same candour to customers. We would rather it were on the product pages. But it is on the record, in the company's own words, and it is worth knowing that the brand you are buying from understands and states the position clearly.
What happens to the THC drinks and gummies in November 2026?
They cannot continue in their present form, and cbdMD's exposure here is the largest we have measured. H.R. 5371, enacted 12 November 2025 and effective 12 November 2026, caps finished consumable products at 0.4 milligrams of total THC per innermost retail container, alongside redefining hemp so the 0.3% limit applies to total THC measured after decarboxylation. The container cap is the provision that bites. cbdMD's catalogue now leans heavily into THC beverages — beverages were the single largest product category when we pulled the catalogue — and the doses are not small. The Unflavored and Citrus THC Mixers are labelled 170mg at $79.99, which is roughly four hundred and twenty-five times a 0.4mg container limit. The 30mg seltzers and shots are seventy-five times over. Even the lowest-dose products on the THC line, at 5mg a serving, are more than twelve times the per-container figure. There is no packaging change or reformulation that fits a 170mg mixer inside a 0.4mg container cap. The CBD tinctures, softgels, topicals and pet products are not affected in the same way, because they are not sold on THC content. If you buy from the THC range, buy it understanding the date.
Does any of this relate to GLP-1 medication?
Not directly, and there are three points worth knowing. cbdMD is a hemp and wellness company; it prescribes nothing, employs no clinicians and sells no product with a role in weight management. If treatment is what you want, our provider rankings are the page to read. The three genuine intersections. First, THC stimulates appetite — it is an agonist at the CB1 receptor, and appetite suppression is the mechanism by which semaglutide and tirzepatide work, so the THC line works against a GLP-1 rather than with it. Second, symptom confusion: GLP-1s commonly cause nausea and vomiting during dose escalation, and heavy chronic cannabis use can cause a cyclical vomiting syndrome that looks similar, so tell your prescriber if you use these products. Third, and most relevant to the sleep items in this range, poor sleep in people carrying excess weight is very often obstructive sleep apnoea, which is common, frequently undiagnosed, and now has a licensed drug treatment — tirzepatide is FDA-approved for moderate-to-severe OSA in adults with obesity. A sedating sleep product can make untreated apnoea feel better while it continues, so snoring, gasping or waking unrefreshed is a reason to ask for a sleep study rather than to buy a gummy.
Can you verify the lab testing?
No, and we want to be precise about what that does and does not mean. cbdMD maintains a dedicated 'COA / lab results' link in its site footer and a page at /pages/coa, which is the right structure and more than some brands offer. When we loaded that page we found no retrievable certificate links and no batch selector we could operate — the only links present were internal anchors. So we were unable to open a single certificate and cannot tell you what any batch tested at, whether contaminant panels are run, or which laboratory performs the work. We are reporting a failure to verify, not an absence of testing. It is entirely possible the page relies on a lookup tool that did not initialise for us, or that certificates are supplied on request or printed with a batch code on the packaging. For comparison, the strongest brand we have reviewed in this category published a four-page accredited certificate covering potency, pesticides, solvents, metals, microbials and mycotoxins, linked directly from the product page — that is the standard that is achievable. If testing documentation matters to you, ask cbdMD for the certificate for your specific batch before ordering and judge the answer.
What does it cost?
More than most of the category, with heavy discounting on top. Checked on 8 August 2026 from the company's own catalogue: full spectrum CBD + CBN and CBD + CBG oil tinctures at $159.99, a Full Spectrum Inferno Freeze roller at $104.99, full spectrum calming gummies at $84.99 against $44.99 for the broad spectrum version, Delta 9 THC Max Dose Nano Gummies at $64.99, Delta 9 Lights Out Sleep Gummies at $59.99, Delta 9 Chill, Relax and Elevate gummies at $49.99, a Delta 9 drink mixer at $39.99, THC Mixers at $79.99, 30mg seltzers and shots at $29.99 with multipacks to $139.99, 10mg versions at $24.99, Delta 9 Micro Mints from $14.99 and a Vibe Bar at $19.99. A '55% Off Sitewide' promotion was running when we looked. Deep sitewide discounting is worth noticing rather than celebrating: it usually means the list prices are not the real prices, and for a company reporting losses it can indicate pressure to convert inventory into cash. Judge value on the discounted price you actually pay, and compare per-milligram against competitors rather than on headline percentages off.
Who should buy from cbdMD and who should not?
Buy if you specifically want this brand's formulations, you are making a single modest purchase, you pay by credit card, and you are comfortable that the 60-day guarantee sits behind a company carrying a going-concern qualification. On those terms it is a legitimate, SEC-reporting business with real quality infrastructure described in its filings and an unusually honest account of the regulatory position. Do not stock up, do not subscribe, do not buy gift cards, and do not accumulate reward points you intend to redeem later — all of those leave your money with the company rather than in your pocket. Skip the THC beverages and gummies if you want something you can keep buying, because a 170mg mixer has no route through the 0.4mg per-container cap arriving on 12 November 2026. Skip the THC products altogether if you are taking a GLP-1, because they stimulate the appetite your medication is suppressing. And if you are buying a sleep product because you sleep badly and carry excess weight, ask a clinician about sleep apnoea first — that is a diagnosis worth having rather than sedating through.
One Item, Credit Card, No Subscription
The guarantee is generous and the company has disclosed doubt about its own continuity. Buy small, take delivery, and leave nothing on account.
Visit cbdMDCompare Other GLP-1 Providers
See how other telehealth providers stack up.
CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →JumpstartMD
Comprehensive ProgramMedically supervised program with obesity medicine physicians, dietitians, and in-person options
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →BeyondMD
Top RatedBoard-certified physician-led care with comprehensive medical oversight
Read Review →Medical & Financial Disclaimer: This page is informational and is neither medical, legal nor financial advice. These are hemp and supplement products, not medicines; they are not intended to diagnose, treat, cure or prevent any disease and are not a substitute for prescribed treatment. The FDA's stated position is that CBD cannot lawfully be marketed as a dietary supplement or added to human food. THC products are intoxicating, are for adults 21 and over where permitted by state law, can impair coordination and judgement, must not be used before driving, and can produce a positive drug test. Do not use if pregnant or breastfeeding, and avoid if you have a personal or family history of psychosis, schizophrenia or bipolar disorder. THC stimulates appetite, which opposes the mechanism of GLP-1 medication; heavy chronic cannabis use can cause cyclical vomiting that may be confused with GLP-1 nausea during dose escalation. Sedating sleep products can worsen obstructive sleep apnoea by reducing upper-airway tone; snoring, witnessed pauses in breathing, gasping or waking unrefreshed warrant a sleep study rather than self-treatment, and tirzepatide is FDA-approved for moderate-to-severe obstructive sleep apnoea in adults with obesity. Financial information is drawn from public SEC filings as at the dates stated, is historical, and is not a forecast, an assessment of solvency, investment advice or a recommendation regarding any security. Consult a licensed clinician before starting or changing any treatment.
Date reviewed: 8 August 2026. Financial and disclosure information is from cbdMD, Inc. (NYSE American: YCBD, CIK 0001644903) filings with the SEC. From the Form 10-K for the fiscal year ended 30 September 2025, filed 19 December 2025: 'We have a history of losses from operations and there are no assurances we will report profitable operations in future periods or continue as a going concern'; 'These and other factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the annual financial statements are issued'; 'The Company's ability to continue as a going concern is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding'; 'The board of directors effected a reverse stock split at a ratio of one-for-eight, effective as of May 6, 2025'; references to regaining compliance with NYSE American continued listing standards including a minimum stockholders' equity requirement of $6,000,000 and to non-compliance status having been removed; the statement that the FDA 'continues to assert that CBD cannot be lawfully marketed as a dietary supplement or added to human food under existing statutory authorities due to CBD's prior investigation as an approved drug'; the acknowledgement that enforcement 'has included warning letters for unapproved drug claims, mislabeling, inadequate testing, and non-compliant animal products'; and the description of 'environmental controls, FEFO-based inventory rotation, product-level traceability, and documented recall protocols'. Reported figures: net loss of $2,040,902 for the year ended 30 September 2025, $283,131 for the quarter ended 31 December 2025 and $1,081,111 for the six months ended 31 March 2026; cash and cash equivalents of $2,261,242 at 30 September 2025 and $2,638,243 at 31 March 2026; stockholders' equity of $7,226,107 at 30 September 2025 and $9,284,749 at 31 March 2026. Prices and product names were read from cbdMD's own public product catalogue on 8 August 2026 and may change, including THC Mixers at $79.99 labelled 170mg, 30mg seltzers and shots at $29.99 with multipacks to $139.99, 10mg versions at $24.99, Delta 9 THC Max Dose Nano Gummies at $64.99 described as 18mg per serving, Delta 9 THC Gummies at $49.99 described as 5mg or 10mg per serving, CBD + CBN and CBD + CBG tinctures at $159.99, an Inferno Freeze roller at $104.99, full spectrum calming gummies at $84.99 and broad spectrum at $44.99; a '55% Off Sitewide' promotion was displayed. The return policy quoted — 'If you are not fully satisfied with your purchase, you may request a full refund on the purchase price within 60 days' — is from the company's own site. The COA page at /pages/coa loaded but yielded no retrievable certificate links or operable batch selector for us, so we did not verify any certificate; this is a failure to verify rather than evidence of absent testing. Trustpilot showed 2.6 out of 5 across 26 reviews, read from Trustpilot's own structured data; a BBB search returned no profile. The Katalys offer lists a default commission of 0.00%. H.R. 5371 was enacted 12 November 2025 and takes effect 12 November 2026, applying the 0.3% limit to total THC after decarboxylation inclusive of THCA and capping finished consumable products at 0.4mg total THC per innermost retail container.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This particular programme pays 0.00% commission. This does not influence our editorial content or review ratings.